Pre-market · Oct 8, 7:50 am ET · After hours $10.00 -1.67%
Open$9.84
Prev close$9.87
Day range$9.68 – $10.75
Volume2.08M
Market cap$867.64M
P/E (TTM)–
Dividend yield–
GLUE Stock News
Headlines matching Monte Rosa Therapeutics or the GLUE ticker, most recent first.
Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Cuts Target Price to $28NegativeMarket news · 7 Aug 2026 · Direct mention
Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)TipRanks · 13 Aug 2026 · Direct mention
J.P. Morgan Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Cuts Target Price to $27NegativeMarket news · 11 Aug 2026 · Direct mention
Jefferies Initiates Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Announces Target Price $25Market news · 1 Aug 2026 · Direct mention
Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $35Market news · 15 Jul 2026 · Direct mention
Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $35PositiveMarket news · 30 Jun 2026 · Direct mention
Wells Fargo Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $29Market news · 24 Jun 2026 · Direct mention
Wedbush Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $37Market news · 9 May 2026 · Direct mention
J.P. Morgan Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $31PositiveMarket news · 11 May 2026 · Direct mention
Analysts Are Bullish on Top Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Sagimet Biosciences, Inc. Class A (SGMT)PositiveTipRanks · 5 Oct 2026 · Direct mention
H.C. Wainwright Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $25Market news · 5 Oct 2026 · Direct mention
Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $28Market news · 2 Oct 2026 · Direct mention
Piper Sandler Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $37Market news · 2 Oct 2026 · Direct mention
LifeSci Capital Maintains Monte Rosa Therapeutics(GLUE.US) With Buy RatingMarket news · 2 Oct 2026 · Direct mention
H.C. Wainwright Initiates Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Announces Target Price $25Market news · 1 Oct 2026 · Direct mention
Discussion
No comments yet — be the first to weigh in on GLUE.
No comments yet — be the first to weigh in on GLUE.